Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIRISE hormonal replacement study after prophylactic adnexectomy in genetically high-risk women
NL-OMON20562Recruiting
- Sponsor
- Initiator : Anca C. Ansink, MD, PHD, gynaecological oncologist Dept. Obstetrics & Gynaecology, room A1-40 Erasmus MC- Daniel den Hoed Oncology Center PO BOX 5201 3008 AE Rotterdam The Netherlands phone: +31 10 4391263 fax +31 10 4391011 E-mail: [email protected] secundary sponsor: NV Organon Molenstraat 110 Postbus 20 5340BH Oss The Netherlands phone+ 31 412661222 fax. +31 412662617
- Start
- Sep 2004
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of conjugated estrogens, medroxyprogesterone acetate and tibolone in Surgical Menopause and menopause (3 arms), sponsored by Initiator : Anca C. Ansink, MD, PHD, gynaecological oncologist Dept. Obstetrics & Gynaecology, room A1-40 Erasmus MC- Daniel den Hoed Oncology Center PO BOX 5201 3008 AE Rotterdam The Netherlands phone: +31 10 4391263 fax +31 10 4391011 E-mail: [email protected] secundary sponsor: NV Organon Molenstraat 110 Postbus 20 5340BH Oss The Netherlands phone+ 31 412661222 fax. +31 412662617. Primary endpoints: Change in mammographic breast density and Menopausal symptoms and sexuality. Started Sep 2004; status: recruiting.
02
Drugs
conjugated estrogensmedroxyprogesterone acetatetibolone
03
Conditions
Surgical Menopausemenopause
Beyond the preview
Go deeper on NL-OMON20562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20562.